The rationale for the use of dopamine agonists in Parkinson's disease.
about
SKF-82958 is a subtype-selective estrogen receptor-alpha (ERalpha ) agonist that induces functional interactions between ERalpha and AP-1Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptorsChronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease.Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey.Ropinirole in restless legs syndrome and periodic limb movement disorderNeurokinin-1 receptor activation in globus pallidusThe effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.Management of motor complications in advanced Parkinson's disease.Dissociable effects of dopamine on neuronal firing rate and synchrony in the dorsal striatum.ADMET considerations for restless leg syndrome drug treatments.Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.Dopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesias.Global and local excitation and inhibition shape the dynamics of the cortico-striatal-thalamo-cortical pathway.Nigrostriatal lesion induces D2-modulated phase-locked activity in the basal ganglia of rats.l-dopa-induced dyskinesias in unilateral 6-hydroxydopamine-lesioned rats are not modified by excitotoxic lesion of the entopeduncular nucleus and substantia nigra pars reticulata.Drug treatment of Parkinson's disease.Levodopa-induced dyskinesia in an autopsy-proven case of progressive supranuclear palsy.Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents.The effects of medication use in transcranial direct current stimulation: A brief review.Cocaine Effects on Dopaminergic Transmission Depend on a Balance between Sigma-1 and Sigma-2 Receptor Expression.
P2860
Q28204373-2F1869DC-7DBD-4BCC-BFC9-3EDAA0EAAA33Q28250152-B4555FC6-1E3D-42DA-9F5E-867F06C4F350Q30484170-A51EF40D-62E3-4E76-850D-017FECAB978DQ32061819-C0022220-C5DF-4D24-A9FF-05D5CF1C0052Q33802191-92FB34D8-AE6C-44FB-BD09-FB0828B7BF66Q33806451-2ADEE46D-471F-4A39-BAAC-225934063D5AQ35042094-44B264C3-0B6C-498C-A679-D75ED0E197A3Q35589979-CF47C621-4577-41C6-8275-9114D522F449Q36318159-E1E40ED4-6804-439A-B9FC-B40E225CF1E7Q37050649-92627119-37B0-47B8-AB29-447E1E89BB79Q37442803-4B47A6DC-DBFE-4F3B-92F0-1D90244D1C7EQ38027180-97C9F177-E1AB-4056-81EF-22C79D7AFDD8Q38162942-7A0724D1-F4E5-4330-A489-86D076A760E4Q38314257-177A5704-07B0-46EB-BA6B-53599E013ABDQ41312152-4D8787F0-0C60-4DFC-AA42-13B7103265DDQ42511232-A68CC019-F49E-4380-AC95-37BB537D382DQ42520633-BE75097B-C8E7-4542-B484-F9324431D727Q42725618-8802D56C-DEC9-4A80-9533-366A128502DEQ44165271-4EE96BCC-D083-412D-8658-FD2C4C0AAD21Q44612074-7BD4831D-77F1-400D-9614-80C307BBC8A3Q46727000-E83302A7-3FA2-4DC9-9BCF-1DD0974896DBQ47729862-0775892E-15E7-441B-9A34-A695C3325685Q50323703-C82EB2F5-57A3-4B4F-BDD0-C770FB7A8AA8
P2860
The rationale for the use of dopamine agonists in Parkinson's disease.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
The rationale for the use of dopamine agonists in Parkinson's disease.
@en
type
label
The rationale for the use of dopamine agonists in Parkinson's disease.
@en
prefLabel
The rationale for the use of dopamine agonists in Parkinson's disease.
@en
P1433
P1476
The rationale for the use of dopamine agonists in Parkinson's disease.
@en
P2093
P356
10.1212/WNL.45.3_SUPPL_3.S6
P407
P433
P577
1995-03-01T00:00:00Z